Skip to main content
. 2021 Sep 29;11:752545. doi: 10.3389/fonc.2021.752545

Table 2.

Summary of responses.

Pembrolizumab group (n = 49) Bevacizumab group (n = 53) P-value
Best overall response, n (%)
 CR 0 0
 PR 18 (36.7) 23 (43.4)
 SD 26 (53.1) 26 (49.1)
 PD 4 (8.2) 3 (5.7)
 No assessment 1 (2.0) 1 (1.9)
ORR (95%CI) 36.7% (23.8% to 51.2%) 43.4% (30.1% to 57.7%) 0.548
DCR (95%CI) 89.8% (77.0% to 96.2%) 92.5% (80.9% to 97.6%) 0.735

CR, complete response; PR, partial response; SD stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.